Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments. It offers OTC products in cough, cold, allergy, sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, animal health, diagnostic, lifestyle, personal care and derma-therapeutics, natural health and vitamins, minerals and dietary supplements, feminine hygiene, diabetes care, scar management, and anti-parasite categories under the Good Sense, Sergeant's, Sentry, Zephrex D, PetArmor, and ScarAway brand names.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone353-1709-4000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.73 billion
Profitability
Miscellaneous
Employees10,600
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable
Perrigo (NYSE:PRGO) Frequently Asked Questions
What is Perrigo's stock symbol?
Perrigo trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRGO."
How often does Perrigo pay dividends? What is the dividend yield for Perrigo?
Perrigo announced a quarterly dividend on Monday, November 4th. Shareholders of record on Friday, November 29th will be given a dividend of $0.21 per share on Tuesday, December 17th. This represents a $0.84 annualized dividend and a yield of 1.41%. The ex-dividend date of this dividend is Wednesday, November 27th. View Perrigo's Dividend History.
How were Perrigo's earnings last quarter?
Perrigo Company PLC (NYSE:PRGO) announced its quarterly earnings results on Wednesday, November, 6th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.93 by $0.11. The business had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.20 billion. Perrigo had a return on equity of 9.39% and a net margin of 5.24%. Perrigo's revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the firm posted $1.09 earnings per share. View Perrigo's Earnings History.
When is Perrigo's next earnings date?
What guidance has Perrigo issued on next quarter's earnings?
Perrigo issued an update on its FY 2019
Pre-Market earnings guidance on Tuesday, January, 14th. The company provided EPS guidance of for the period. The company issued revenue guidance of $4.797-4.797 billion, compared to the consensus revenue estimate of $4.77 billion.
What price target have analysts set for PRGO?
6 Wall Street analysts have issued 1 year target prices for Perrigo's shares. Their forecasts range from $48.00 to $60.00. On average, they anticipate Perrigo's share price to reach $53.80 in the next twelve months. This suggests that the stock has a possible downside of 9.7%. View Analyst Price Targets for Perrigo.
What is the consensus analysts' recommendation for Perrigo?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Perrigo in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Perrigo.
Has Perrigo been receiving favorable news coverage?
Media coverage about PRGO stock has trended positive on Friday, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Perrigo earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Perrigo.
Who are some of Perrigo's key competitors?
Some companies that are related to Perrigo include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).
What other stocks do shareholders of Perrigo own?
Who are Perrigo's key executives?
Perrigo's management team includes the folowing people:
- Mr. Murray S. Kessler, CEO, Pres & Director (Age 59)
- Mr. Todd W. Kingma, Exec. VP, Gen. Counsel & Sec. (Age 59)
- Mr. Jeffrey R. Needham, Exec. VP & Pres of Consumer Healthcare Americas (Age 63)
- Mr. Svend Andersen, Exec. VP & Pres of Consumer Healthcare International (Age 57)
- Mr. Ronald L. Winowiecki, Advisory (Age 53)
Who are Perrigo's major shareholders?
Perrigo's stock is owned by many different of retail and institutional investors. Top institutional investors include Manning & Napier Group LLC (0.35%), State of Alaska Department of Revenue (0.07%), FTB Advisors Inc. (0.05%), Moon Capital Management LLC (0.03%), Sciencast Management LP (0.02%) and Contravisory Investment Management Inc. (0.00%). Company insiders that own Perrigo stock include Geoffrey M Parker, Grainne Quinn, Jeffrey C Smith, Murray S Kessler, Ronald Craig Janish, Ronald Winowiecki, Svend Andersen, Theodore R Samuels II, Todd W Kingma and Uwe Roehrhoff. View Institutional Ownership Trends for Perrigo.
Which major investors are selling Perrigo stock?
PRGO stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, State of Alaska Department of Revenue, Moon Capital Management LLC and FTB Advisors Inc.. Company insiders that have sold Perrigo company stock in the last year include Grainne Quinn, Ronald Craig Janish, Ronald Winowiecki and Todd W Kingma. View Insider Buying and Selling for Perrigo.
Which major investors are buying Perrigo stock?
PRGO stock was bought by a variety of institutional investors in the last quarter, including Sciencast Management LP and Contravisory Investment Management Inc.. Company insiders that have bought Perrigo stock in the last two years include Geoffrey M Parker, Jeffrey C Smith, Murray S Kessler, Svend Andersen, Theodore R Samuels II, Todd W Kingma and Uwe Roehrhoff. View Insider Buying and Selling for Perrigo.
How do I buy shares of Perrigo?
Shares of PRGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Perrigo's stock price today?
One share of PRGO stock can currently be purchased for approximately $59.57.
How big of a company is Perrigo?
Perrigo has a market capitalization of $8.11 billion and generates $4.73 billion in revenue each year. The company earns $131 million in net income (profit) each year or $4.55 on an earnings per share basis. Perrigo employs 10,600 workers across the globe.View Additional Information About Perrigo.
What is Perrigo's official website?
How can I contact Perrigo?
Perrigo's mailing address is THE SHARP BUILDING HOGAN PLACE, DUBLIN L2, 49010. The company can be reached via phone at 353-1709-4000 or via email at [email protected]
MarketBeat Community Rating for Perrigo (NYSE PRGO)
MarketBeat's community ratings are surveys of what our community members think about Perrigo and other stocks. Vote "Outperform" if you believe PRGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRGO will underperform the S&P 500 over the long term. You may vote once every thirty days.
